Recent evidence shows that human neutrophil elastase inhibitors can be synthesized locally at mucosal sites. In addition to efficiently targeting bacterial and host enzymes, they can be released in the interstitium and in the lumen of mucosa, where they have been shown to have antimicrobial activities, and to activate innate immune responses. This review will address more particularly the pleiotropic functions of low-molecularmass neutrophil elastase inhibitors [SLPI (secretory leucocyte proteinase inhibitor) and elafin] and, more specifically, their role in the development of the adaptive immune response.
Introduction
The respiratory surface is continually exposed to potentially injurious particulates and pathogenic organisms, to which tightly regulated innate immunological responses are made. These facilitate bacterial clearance and epithelial activation without significant loss of respiratory function. Serine proteinase inhibitors are central to this control paradigm with their proteinase inhibitory activity [1] , direct antimicrobial function [1] [2] [3] [4] and cytokine-modulating ability [3] . However, if early innate mechanisms do not succeed in removing the foreign matter, an inflammatory immune response results, which, if not regulated, can lead to the induction of fibrosis and scarring. This review will highlight the role of three serine proteinase inhibitors, α 1 -PI (α1 proteinase inhibitor; also known as α 1 -antitrypsin), SLPI (secretory leucocyte proteinase inhibitor) and elafin, in acute and adaptive immunity, highlighting potential therapeutic applications.
HNE (human neutrophil elastase)
The predominant target of the serine proteinase inhibitors discussed here is HNE. HNE is a member of the chymotrypsin superfamily of serine proteinases, expressed in monocytes and mast cells, but primarily by neutrophils, where it is compartmentalized into azurophil granules. The intracellular function of this enzyme is the degradation of foreign microorganisms that are phagocytosed by the neutrophil. However, upon overzealous cellular activation, HNE is rapidly emptied into the extracellular space where it can also inactivate bacteria [5] . Secreted HNE can also degrade local ECM (extracellular Key words: α1 proteinase inhibitor, elafin, elastase, secretory leucocyte proteinase inhibitor (SLPI). Abbreviations used: α1-PI, α1 proteinase inhibitor; CF, cystic fibrosis; COPD, chronic obstructive pulmonary disease; ECM, extracellular matrix; HNE, human neutrophil elastase; IκB, inhibitory κB; IL, interleukin; LPS, lipopolysaccharide; MMP, matrix metalloproteinase; NF-κB, nuclear factor κB; SLPI, secretory leucocyte proteinase inhibitor; TNFα, tumour necrosis factor α. 1 To whom correspondence should be addressed (email J.Sallenave@ed.ac.uk). matrix) proteins, remodel damaged tissue, and can facilitate neutrophil migration into or through tissue [6] , although studies in HNE-knockout mice would suggest that this function is not essential for normal neutrophil trafficking [7] . Secretion of HNE also modulates cytokine expression at epithelial and endothelial surfaces, up-regulating cytokines such as IL-6 (interleukin-6), IL-8, TGF-β (transforming growth factor β) and GM-CSF (granulocyte/macrophage colony-stimulating factor), while promoting the degradation of cytokines such as IL-1, TNFα (tumour necrosis factor α) and IL-2 and -6 (reviewed more extensively in [8, 9] ).
Innate HNE-mediated cytokine modulation has the potential to influence the initiation and polarization of adaptive immune responses. Recent studies in our laboratory would suggest that HNE may also have more direct effects in this process, cleaving the dendritic cell CSMs (co-stimulatory molecules) CD40, CD80 and CD86, which are essential for the stimulation of adaptive immunity, reducing T-lymphocyte stimulatory capacity [10] . Further to this, studies by Doring et al. [11] suggest that HNE and cathepsin G, another neutrophil product, can cleave T-cell surface proteins that are involved in cell-cell interactions and activation, which may lead to reduced T-lymphocyte functionality in neutrophilrich areas.
These findings are of particular interest, given that a growing body of evidence would suggest that superfluous HNE is one of the major pathological factors in the development of several chronic inflammatory lung conditions such as CF (cystic fibrosis) and COPD (chronic obstructive pulmonary disease), and that exacerbations in these conditions may be initiated by a failure to clear bacterial infections [12] .
Proteinase inhibitors
The serine proteinase inhibitors constitute a pleiotropic group of molecules that are capable of limiting the function of potentially injurious pathogen and host-derived proteinases.
These molecules can be broadly classified into two groups, the systemic and the alarm proteinase inhibitors.
Although some epithelial surfaces and cells of the immune system may produce small quantities of systemic proteinase inhibitors, such as α 1 -PI [13] , they are produced primarily by hepatocytes and constitute a circulatory source of anti-proteinase activity which acts as a protective shield against proteinase-induced injury. However, during infection and/or heightened HNE release, this protective shield can be overcome and is supplemented by the activity of the alarm proteinase inhibitors such as SLPI and elafin.
Produced by epithelial cells and cells of the immune system, alarm proteinase inhibitors are generated locally in areas of infection or neutrophil infiltration and are up-regulated by pathogen-and inflammation-associated factors, including HNE itself [14] . Another distinguishing factor between these types of proteinase inhibitor is size. α 1 -PI is approx. 52 kDa in size and α 2 -macroglobulin, another systemic proteinase inhibitor, is 725 kDa. This is in contrast with the alarm proteinase inhibitors SLPI and elafin, which are 11.7 kDa and 9.9 kDa respectively.
The archetypical systemic proteinase inhibitor is α 1 -PI. Although this enzyme can inhibit various proteinases, including protease 3, cathepsin G and plasminogen activator, its main target is HNE. The development of emphysema in humans with a congenital deficiency of the α1-PI gene would suggest that the primary function of this inhibition is the prevention of connective tissue damage. α 1 -PI is synthesized by hepatocytes and is secreted into plasma with a half-life of 4.4 days. During periods of intense inflammation, circulatory levels can rise 3-fold in response to IL-6 and other circulatory cytokine signals [15] . α 1 -PI-mediated inactivation of HNE occurs via a permanent covalent attachment [16] and accounts for approx. 92% of HNE inhibition in the sera. The remaining inhibition occurs via another systemic proteinase inhibitor, α 2 -macroglobulin, which inhibits by structural obstruction of the proteinase moiety, but in a manner which does not completely block HNE activity [17] . SLPI SLPI is a highly conserved proteinase inhibitor produced constitutively by epithelium, mast cells, neutrophils and macrophages. Despite circulating in blood, the dominance of α 1 -PI in this environment means that most biologically significant SLPI function occurs at epithelial surfaces such as in the mucosal lining fluids, where, although SLPI occurs at a concentration approximately half that of α 1 -PI, it can be found associated with elastin fibres [18] .
SLPI is a boomerang-shaped molecule that comprises two topologically superimposible domains. The proteinase inhibitory domain of SLPI is located in the C-terminus and primarily inhibits HNE, but is capable of inhibiting a range of other proteinases, such as Clara-cell-produced tryptase, which is responsible for much of the infectivity of Sendai virus and influenza A [19] . The N-terminus of SLPI is highly cationic, enabling it to disrupt cellular membranes, a feature used to explain its recently identified antimicrobial activity directed at the bacteria Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus epidermis and group A Streptococcus, and the fungi Aspergillus fumigatus and Candida albicans [20] .
The terminal domains of SLPI have also been shown to influence the activity of monocytes and macrophages, which, like neutrophils, are responsible for ECM disruption in emphysema and other chronic lung inflammatory conditions. N-terminal SLPI, for example, can suppress prostaglandin E 2 production in macrophages, which results in reduced production of the MMP (matrix metalloproteinase) proteins MMP1 and MMP9 [21] . SLPI expression has also been shown to limit LPS (lipopolysaccharide) responsiveness in macrophage. This occurs with both the N-and C-termini independently and does not require an active proteinase inhibitor domain [22] . A number of mechanisms have been elucidated for this activity including LPS-CD14 complex disruption [23] and SLPI-mediated preservation of IκB (inhibitory κB) expression [an endogenous inhibitor of NF-κB (nuclear factor κB)] [24, 25] .
Further SLPI functions unrelated to bactericidal or proteinase inhibitory activity include the down-regulation of lipoteichoic acid responsiveness in monocytes [26] , the inhibition of neutrophil phagocytosis and oxidative burst in an immune-complex-induced arthritis model [27] and antiviral activity against HIV [28] .
Elafin
Elafin is produced as a 9.9 kDa full-length active protein composed of an N-terminal 'cementoin' domain which facilitates transglutaminase-mediated cross-linkage on to polymers or ECM components [29] and a globular C-terminus, containing the proteinase inhibitor moiety, the primary substrate of which is HNE [1] . The C-terminus has also been identified separately in human lung secretions [30] , possibly generated from the full-length molecule by tryptase-mediated cleavage [31] .
Elafin is reasonably well conserved across most species except for mice, which lack a direct homologue, although elafin-like molecules have been identified [32] . Human epithelial cell line studies would suggest that, in contrast with SLPI, constitutively produced levels of elafin are low [14] , but that elafin levels are more responsive to IL-1, TNFα, LPS and HNE [14, 33] . Despite contrasting expression profiles, elafin shares many functional characteristics with SLPI, such as antimicrobial activity against both Gram-negative andpositive bacteria [1, 4] , modulation of NF-κB signalling [25] and LPS binding [3] .
Antimicrobial functions for elafin have been identified with Ps. aeruginosa and Staph. aureus [20] . Interestingly, unlike SLPI whose antimicrobial domain resides primarily in the N-terminus, the bactericidal function of elafin is unlikely to be solely a consequence of the cationic N-terminus, as, although this was found to be the bactericidal domain with Ps. aeruginosa, the C-terminus was the primary bactericidal domain with Staph. aureus, and full-length elafin had greater bactericidal activity with both organisms [1] .
Like SLPI, elafin-mediated disruption of LPS responses in macrophages is associated with the preservation of IκB. Importantly, studies by Henriksen et al. [25] illustrated that this mechanism also abrogated HNE-, TNFα-and oxidized LDL (low-density lipoprotein)-mediated activation of HUVECs (human umbilical vein endothelial cells). Elafin has also been shown to bind directly to smooth LPS in the same locality as SLPI, LBP (LPS-binding protein) and polymyxin B, by both of the N-and C-terminal domains, although it is primarily the C-terminal binding which results in reduced TNFα production by LPS-stimulated macrophages [3] . In contrast, if serum is removed from this system, C-terminal elafin-LPS binding results in increased TNFα production by macrophage. Similarly, contrasting functions have been observed in vivo, where elafin results in pro-inflammatory effects with LPS instillation [34] , but is anti-inflammatory with pulmonary bacterial colonization [2, 35] . Thus it would appear that elafin may have dual functions, being pro-inflammatory under serum-starved conditions similar to the normal respiratory surface, but antiinflammatory when serum is present, such as with vascular leakage in acute lung injury or bacterial infection.
Elafin may also play a role in the resolution of inflammation by protecting against HNE-mediated cleavage of receptors which are essential for the recognition and engulfment of apoptotic cells, preventing potentially injurious secondary apoptosis which may prolong the inflammatory process [36] [37] [38] . In addition to this, studies from our laboratory have shown that elafin has significant potential in the modulation of antigen-presenting cell numbers and activity in vivo [39] . Furthermore, analysis of BALF (bronchoalveolar fluid) cytokine levels and antibody subclasses indicates that elafinexpressing mice may have a 'type 1' bias with adenoviral infection [39] .
Therapeutic applications
Excessive HNE beyond levels controlled by endogenous proteinase inhibitors have been identified in a number of severe and progressive inflammatory disorders such as CF, COPD, ARDS (acute respiratory distress syndrome) and pulmonary fibrosis, and is associated with asthmatic exacerbations. Rising antibiotic resistance and a need to develop novel methods to tackle persistent infections in these conditions has led to an increased interest in serine proteinase inhibitors as potential therapeutics.
Method of delivery
Effective proteinase inhibitor therapeutic intervention will probably depend on the correct targeting of tissues and conditions through specific methods of delivery. Hypothetically, the most direct method of administration possible is transfection of transferred material in grafting or transplant procedures. Studies in rabbit, for example, using transient elafin transfections of vein grafts demonstrated a 60% reduction in inflammation at 48 h post-transplantation, with a longer-term reduction in cholesterol-induced macrophage infiltration and lipid accumulation. These findings suggested that transient elafin expression was sufficient to reduce subsequent atherosclerosis, a condition common to these procedures [40] , but with wider implications for the systemic administration of proteinase inhibitors in the treatment of peripheral and coronary disease of the arteries, which has been associated with HNE activity [41] . However, the dominance of α 1 -PI as a circulatory proteinase and the low proportion of infused inhibitors which reach the epithelial surfaces affected in many HNE-related conditions [42] will probably limit the value of circulatory proteinase inhibitor supplementation.
The treatment of respiratory conditions with aerosolized proteinase inhibitors is perhaps the most promising therapeutic system, as preliminary studies suggest that proteinase inhibitors are unaffected by the aerosolization process, can be delivered directly to their desired location when required and demonstrate sustained half-lives in lung fluid [43] . However, the inhalation route of delivery has its own inherent complications, such as consistent efficiency of the delivery device, and regional variation in deposition and the resulting dosage at different sites.
Clinical application
Historically, most trials have concentrated on systemic proteinase inhibitors such as α 1 -PI, the genetics and expression of which were better understood than for many of the alarm proteinase inhibitors. Hereditary emphysema, associated with a congenital deficiency of α 1 -PI, has been one heavily trialled condition. However replacement therapy using α 1 -PI isolated from donor blood remains the main method of treatment, although limited blood donors, frequency of treatment and cost have all limited the delivery of this treatment to patients.
Recent elucidations of the multifunctional role of the alarm proteinase inhibitors have encouraged greater research into their application. The alarm proteinase inhibitors have a number of advantages over systemic inhibitors as discussed in a review by Vogelmeier et al. [44] . First, SLPI is easier to produce synthetically as it is not glycosylated; therefore it can be expressed in prokaryotes and retained in vivo like native peptide (<0.2% excreted within 5 h of delivery). This contrasts with recombinant α 1 -PI which lacks carbohydrate side chains that are present in the natural form, resulting in a reduced biological half-life with excretion within minutes of intravenous delivery. Secondly, the cementoin domain of elafin and the elastin association of SLPI means that after aerosolized delivery, they are retained in the lung and interstitium with a half-life of 12 h in lung fluid [43] . This is in stark contrast with aerosolized α 1 -PI which diffuses more readily from its desired target site [43] . Thirdly, sites high in HNE are generally also high in other inflammatory-celland pathogen-derived factors, such as MMP8 and oxidizing mediators which can inactivate proteinase inhibitors [45] . However, unlike α 1 -PI, SLPI and elafin are not inactivated by MMP8 [46] . Further to this, studies by Gillissen et al. [47] in sheep indicate that SLPI can counter oxidative inactivation by up-regulating the antioxidant glutathione thus SLPI may be applicable to the treatment of conditions, such as COPD, which are rich in oxidants.
Although cigarette smoking is the accepted cause for COPD, exacerbations of the disease are associated with low SLPI levels [48] and viral and bacterial infections [12] identified in the lungs of the majority of COPD patients. Delivery of exogenous proteinase inhibitors to this system has the potential to up-regulate antioxidant enzymes, increasing endogenous proteinase inhibitor function, to restore normal apoptotic cell clearance mechanisms and to facilitate normal dendritic-cell-mediated adaptive immune responses. However, the limited access to airways in COPD attributable to mucous plugs, which limits the effectiveness of bronchodilators and corticosteroid applications, will also limit proteinase inhibitor therapy. Thus it is likely that productive approaches to the treatment of COPD will occur via a combined systemic and aerosolization approach. A similar combined approach would probably be required for the treatment of CF patients who also have restricted airway access and could benefit from the antimicrobial functions of the serine proteinase inhibitors, as these patients die primarily from bronchiectasis and respiratory failure resulting from protracted inflammatory infiltration associated with recurrent bacterial and viral infections [49] .
In conclusion, emerging from the current literature is the notion that, as more immune-modulating functions for proteinases are elucidated, and the multifunctional role of proteinase inhibitors is clarified, they will become evermore attractive as therapeutics for a range of disease aetiologies. Increasingly, more virulent strains of bacteria and antibiotic resistance mean that proteinase inhibitors have the capacity to become the next 'magic bullet'.
